Bank of America
BBIO icon

Bank of America’s BridgeBio Pharma BBIO Stock Holding History

Bank of America’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92M Sell
1,235,380
-50,368
-4% -$3.53M 0.01% 1254
2026
Q1 		$95.5M Buy
1,285,748
+207,700
+19% +$15.1M 0.01% 1155
2025
Q4 		$82.5M Sell
1,078,048
-302,820
-22% -$19.9M 0.01% 1221
2025
Q3 		$71.7M Buy
1,380,868
+279,359
+25% +$13.6M ﹤0.01% 1439
2025
Q2 		$47.6M Buy
1,101,509
+154,659
+16% +$5.63M ﹤0.01% 1748
2025
Q1 		$32.7M Buy
946,850
+511,899
+118% +$17.3M ﹤0.01% 1974
2024
Q4 		$11.9M Sell
434,951
-43,522
-9% -$1.12M ﹤0.01% 2770
2024
Q3 		$12.2M Sell
478,473
-164,787
-26% -$4.33M ﹤0.01% 2887
2024
Q2 		$16.3M Sell
643,260
-174,482
-21% -$4.77M ﹤0.01% 2453
2024
Q1 		$25.3M Buy
817,742
+393,504
+93% +$13.4M ﹤0.01% 2053
2023
Q4 		$17.1M Sell
424,238
-324,859
-43% -$9.76M ﹤0.01% 2324
2023
Q3 		$19.8M Buy
749,097
+24,389
+3% +$692K ﹤0.01% 2043
2023
Q2 		$12.5M Sell
724,708
-640,349
-47% -$9.63M ﹤0.01% 2492
2023
Q1 		$22.6M Buy
1,365,057
+519,245
+61% +$6.05M ﹤0.01% 2001
2022
Q4 		$6.45M Buy
845,812
+310,483
+58% +$2.97M ﹤0.01% 3149
2022
Q3 		$5.32M Sell
535,329
-24,602
-4% -$256K ﹤0.01% 3288
2022
Q2 		$5.08M Sell
559,931
-576,140
-51% -$4.82M ﹤0.01% 3377
2022
Q1 		$11.5M Buy
1,136,071
+512,411
+82% +$5.26M ﹤0.01% 2726
2021
Q4 		$10.4M Buy
623,660
+135,616
+28% +$5.74M ﹤0.01% 2891
2021
Q3 		$22.9M Sell
488,044
-54,393
-10% -$2.92M ﹤0.01% 2057
2021
Q2 		$33.1M Buy
542,437
+322,167
+146% +$18.4M ﹤0.01% 1679
2021
Q1 		$13.6M Buy
220,270
+153,610
+230% +$10M ﹤0.01% 2416
2020
Q4 		$4.74M Buy
66,660
+29,832
+81% +$1.44M ﹤0.01% 3180
2020
Q3 		$1.38M Buy
36,828
+14,748
+67% +$464K ﹤0.01% 3957
2020
Q2 		$720K Buy
22,080
+1,621
+8% +$49.4K ﹤0.01% 4360
2020
Q1 		$594K Sell
20,459
-19,494
-49% -$604K ﹤0.01% 4389
2019
Q4 		$1.4M Buy
39,953
+35,086
+721% +$973K ﹤0.01% 4267
2019
Q3 		$104K Buy
+4,867
New +$135K ﹤0.01% 6027

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bank of America's BBIO Position: Q2 2026 in Review

Bank of America reduced its BridgeBio Pharma (BBIO) stake by 3.9% in Q2 2026, selling an estimated $3.53M and leaving 1,235,380 shares worth $92M. The position accounts for 0.01% of the portfolio, ranked #1254.

Bank of America first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $95.5M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Bank of America held 1,235,380 shares of BridgeBio Pharma worth $92M as of Q2 2026.
  • Bank of America sold 50,368 BridgeBio Pharma shares in Q2 2026, an estimated $3.53M.
  • BridgeBio Pharma made up 0.01% of Bank of America's portfolio in Q2 2026, its #1254 holding.
  • Bank of America first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • Bank of America's BridgeBio Pharma position peaked at $95.5M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.